Surgical Strategy for Head and Neck Adenoid Cystic Cancer

Refining Surgical Strategies Based on Tumor Staging in Head and Neck Adenoid Cystic Carcinoma: Evidence from a Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06778915

Enrollment

309

Registered

2025-01-16

Start date

2016-01-01

Completion date

2024-08-30

Last updated

2025-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoid Cystic Carcinoma

Brief summary

To investigate the relationship between surgical margins and outcomes across different tumor stages, in order to provide evidence and guidance for refining stage-specific surgical approaches.

Detailed description

Adenoid cystic carcinoma of the head and neck (HNACC) presents unique surgical challenges due to its propensity for perineural spread and proximity to critical craniofacial structures. While surgical resection remains the cornerstone of treatment, determining the optimal extent of resection to balance oncologic control and functional preservation requires further investigation. The investigator aimed to investigate the relationship between surgical margins and outcomes across different tumor stages, in order to provide evidence and guidance for refining stage-specific surgical approaches.

Interventions

PROCEDUREsurgery

surgery

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients who underwent surgical resection with curative intent and PORT.

Exclusion criteria

* underwent only biopsy, presented with distant metastases or second primary malignancies at initial diagnosis, had incomplete clinical or histopathologic data, or had histologic evidence of high-grade transformation.

Design outcomes

Primary

Measure	Time frame	Description
Local control	5 year	defined as the absence of tumor persistence, recurrence, or progression at the primary tumor site following the completion of treatment, assessed by clinical examination and imaging at designated follow-up intervals.

Secondary

Measure	Time frame	Description
Locoregional Recurrence-Free Survival (LRRFS)	5 year	time from treatment initiation to either locoregional recurrence or death from any cause
Overall Survival (OS)	5 year	time from treatment initiation to death from any cause
Distant Metastasis-Free Survival (DMFS)	5 year	time from treatment initiation to either distant metastasis or death from any cause

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026